ONCO

Onconetix Inc

6.95

Nov 06 • 3:59 PM ET +1.46 (26.59%)

7.17

Aftermarket • 7:59 PM ET +0.22 (3.17%)

Healthcare Biotechnology USA Nano NASD

Nov 06, 11:04 AM1-for-10 reverse split takes effect, Onconetix jumps 31% during regular hours

Peers: CDIO KAPA VERU CAI ANIX KSCP RR KITT SERV PDYN

Scroll to Statements

Index	-
Market Cap	4.09M
Enterprise Value	-1.61M
Income	-10.20M
Sales	0.60M
Book/sh	35.50
Cash/sh	10.02
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	2
IPO	Feb 18, 2022

P/E	0.00
Forward P/E	-
PEG	-
P/S	6.82
P/B	0.20
P/C	0.69
P/FCF	-
EV/EBITDA	-
EV/Sales	-2.68
Quick Ratio	2.00
Current Ratio	2.20
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	No / No

EPS (ttm)	3103.90
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	83.59% -
Sales past 3/5Y	- -
EPS Y/Y TTM	99.22%
Sales Y/Y TTM	-51.33%
EPS Q/Q	-
Sales Q/Q	-83.90%
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	0.11%
Insider Trans	0.00%
Inst Own	8.89%
Inst Trans	-
ROA	-57.40%
ROE	-105.20%
ROIC	-40.10%
Gross Margin	80.40%
Oper. Margin	-
Profit Margin	-
SMA20	33.02%
SMA50	5.95%
SMA200	-94.14%
Trades

Shs Outstand	0.59M
Shs Float	0.39M
Short Float	9.87%
Short Ratio	0.10
Short Interest	0.04M
52W High	1610.00 -99.57%
52W Low	3.42 103.04%
Volatility	20.19% 15.95%
ATR (14)	1.05
RSI (14)	57.26
Beta	2.52
Rel Volume	2.03
Avg Volume	376.80K
Volume	763,443

Perf Week	23.89%
Perf Month	6.22%
Perf Quarter	-22.56%
Perf Half Y	-81.71%
Perf YTD	-99.11%
Perf Year	-99.48%
Perf 3Y	-100.00%
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	5.49
Price	6.95
Change %	26.59%

Oct-27-26 08:30AM	Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement (GlobeNewswire) +18.92%
Oct-26-26 05:03PM	Onconetix Announces Reverse Stock Split (GlobeNewswire)
Oct-23-26 08:30AM	Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition (GlobeNewswire)
Sep-14-26 12:50PM	CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition (GlobeNewswire) -15.73%
08:30AM	Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition (GlobeNewswire)
08:30AM	Loading…
Sep-03-26 08:30AM	Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events (GlobeNewswire) +9.60%
Aug-12-26 07:30AM	Realbotix Reports Financial Results for Q3-2026 (Business Wire) -7.91%
Aug-06-26 08:30AM	Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series (GlobeNewswire) -10.08%
Aug-05-26 08:30AM	Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG (GlobeNewswire) +20.42%
Jul-22-26 11:25AM	Realbotix Corp. Provides Corporate Structure and Operations Update (Business Wire)
Jul-07-26 09:00AM	Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation (GlobeNewswire)
Jun-24-26 08:30AM	Onconetix Highlights Realbotix's Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District (GlobeNewswire) -6.54%
May-19-26 08:00AM	Onconetix, Inc. Announces 1-for-10 Reverse Stock Split (GlobeNewswire) -61.56%
07:30AM	Realbotix Provides Update on Nasdaq Listing (Business Wire)
May-13-26 09:25AM	Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study (GlobeNewswire) -5.10%
10:30AM	Loading…
Apr-27-26 10:30AM	BC-Most Active Stocks (Associated Press) +26.31%
Apr-09-26 10:30AM	BC-Most Active Stocks (Associated Press) +7.96%
08:30AM	Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson (GlobeNewswire)
Apr-02-26 08:30AM	Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update (GlobeNewswire) -18.94%
Mar-31-26 08:30AM	Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors (GlobeNewswire) -5.10%
Mar-27-26 10:30AM	BC-Most Active Stocks (Associated Press) -39.75%
Mar-25-26 12:47PM	Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration (GlobeNewswire) +5.67%
Mar-23-26 08:30AM	Onconetix, Inc. Announces 1-for-5 Reverse Stock Split (GlobeNewswire)
Feb-12-26 08:00AM	Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer (Business Wire) -42.70%
08:00AM	Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company (GlobeNewswire)
Oct-07-25 08:00AM	Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms (PR Newswire) +9.77%
Sep-27-25 08:40AM	Onconetix announces financing through private placement, debt settlement (TipRanks)
Sep-26-25 08:30AM	Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc. (GlobeNewswire) +6.27%
08:15AM	Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement (GlobeNewswire)
Sep-22-25 08:00AM	Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM (GlobeNewswire)
10:30AM	Loading…
Jul-31-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +10.90%
Jul-16-25 08:17AM	Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement (GlobeNewswire) -22.52%
Jun-16-25 08:22AM	Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel (GlobeNewswire) -9.94%
Jun-11-25 11:30AM	Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders (GlobeNewswire) -15.89%
May-23-25 05:00PM	Onconetix receives additional delisting notice from Nasdaq (TipRanks) -14.00%
May-22-25 04:50PM	Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq (GlobeNewswire)
Apr-30-25 06:13PM	Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq (GlobeNewswire) +6.84%
Apr-08-25 08:30AM	Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc. (GlobeNewswire) -5.97%
Mar-25-25 08:50AM	Onconetix claims validation of prostate cancer test Proclarix in Danish cohort (TipRanks) -17.53%
Mar-24-25 08:45AM	Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort (GlobeNewswire) -6.41%
Mar-19-25 08:00AM	Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress (GlobeNewswire)
Dec-12-24 05:00PM	Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing (GlobeNewswire) -23.56% -13.92%
Oct-03-24 04:45PM	Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit (GlobeNewswire)
09:05AM	Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit (GlobeNewswire)
Sep-20-24 11:45AM	Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders (GlobeNewswire) -28.66%
Jul-15-24 06:00AM	Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds (GlobeNewswire)
Jul-11-24 08:17AM	Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds (GlobeNewswire)
May-30-24 07:47AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -19.33%
May-21-24 09:52AM	ONCO Stock Earnings: Onconetix Reported Results for Q1 2024 (InvestorPlace) -15.98%
Feb-13-24 06:00AM	Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors (GlobeNewswire)
Dec-19-23 07:00AM	Onconetix Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders (GlobeNewswire) -16.67%
Dec-18-23 07:00AM	Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix (GlobeNewswire)
Nov-02-23 07:00AM	Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company (GlobeNewswire) +6.08%
Nov-01-23 07:00AM	Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1) (GlobeNewswire)
Oct-30-23 07:00AM	Blue Water Biotech Issues Letter to Shareholders (GlobeNewswire)
Oct-10-23 09:00AM	Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO (GlobeNewswire)
Aug-28-23 04:30PM	Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q (GlobeNewswire)
Aug-10-23 09:00AM	Blue Water Biotech and Copay Consultants Collaborate to Build Copay Assistance Programs for Blue Waters Commercial Products (GlobeNewswire)
Aug-03-23 01:02PM	Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds (GlobeNewswire)
Aug-01-23 08:00AM	Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds (GlobeNewswire)
Jul-31-23 09:00AM	Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians (GlobeNewswire)
Jul-25-23 09:00AM	Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI® (GlobeNewswire)
Jul-17-23 09:00AM	Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities (GlobeNewswire)
Jul-11-23 09:00AM	Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support (GlobeNewswire)
Jul-06-23 05:05PM	Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products (GlobeNewswire)
07:30AM	Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio (GlobeNewswire)
Jun-28-23 03:51PM	Monkeypox Vaccine: Blue Water Biotech Touts Encouraging Preclinical Data From Monkeypox Vaccine Candidate (Benzinga)
07:55AM	Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform (GlobeNewswire)
Jun-21-23 07:30AM	Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio (GlobeNewswire)
Jun-15-23 09:37AM	Blue Water (BWV) Up on Acquisition of 6 FDA-Approved Drugs (Zacks) -6.25%
07:32AM	Will Blue Water Biotech (NASDAQ:BWV) Spend Its Cash Wisely? (Simply Wall St.)
Jun-14-23 07:30AM	Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas (GlobeNewswire) +62.03%
May-12-23 06:32PM	Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire) +5.03%
May-10-23 12:15PM	Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY (GlobeNewswire)
Apr-26-23 03:44PM	Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer (GlobeNewswire)
Apr-25-23 08:00AM	Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI® (GlobeNewswire)
Apr-24-23 08:00AM	Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company (GlobeNewswire)
Apr-20-23 07:30AM	Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset (GlobeNewswire)
06:45AM	Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones (GlobeNewswire)
Apr-12-23 08:30AM	Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated, Orally Delivered Chlamydia Vaccine (GlobeNewswire)
Apr-07-23 08:03AM	1st ocean fish farm proposed for East Coast off New England (AP Finance)
Mar-09-23 08:30AM	Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-06-23 10:15AM	Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development (GlobeNewswire)
Feb-01-23 09:15AM	Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates (GlobeNewswire)
Jan-17-23 08:30AM	Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors (GlobeNewswire) -5.60%
Jan-09-23 08:30AM	Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco (GlobeNewswire)
Dec-12-22 08:30AM	Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives Buy Rating From Both (GlobeNewswire)
Dec-06-22 08:30AM	Blue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine Candidate (GlobeNewswire) -7.94%
Dec-03-22 07:35AM	Blue Water Vaccines (NASDAQ:BWV) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Dec-01-22 08:30AM	Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022 (GlobeNewswire)
Nov-22-22 12:49PM	Fred Smith Co. turns quick $24M deal for Chatham quarry (American City Business Journals)
Nov-21-22 10:18AM	Blue Water Vaccines Shares Jump After Licensing Pact For Chlamydia Vaccine Candidate (Benzinga) +12.28%
08:00AM	Blue Water Vaccines Announces Exclusive, Global License Agreement for Chlamydia Vaccine Candidate Development from The University of Texas Health San Antonio (GlobeNewswire)
Nov-10-22 08:47AM	Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program (GlobeNewswire) +16.32%
Nov-08-22 08:30AM	Blue Water Vaccines Announces Appointment of Vuk Jeremi, Previous Chair of the Council of Europes Committee of Ministers and Previous President of the United Nations General Assembly, to Its Board of Directors (GlobeNewswire) -6.19%
Oct-11-22 09:15AM	Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia at the World Vaccine Congress in Barcelona (GlobeNewswire) -5.92%
Sep-21-22 08:00AM	Blue Water Vaccines to Present at World Vaccine Congress Europe 2022 (GlobeNewswire) -8.26%
Sep-08-22 10:30AM	Blue Water Vaccines to Present In Person and via Webcast at H.C. Wainwrights 24th Annual Global Investment Conference in New York, NY (GlobeNewswire)
Aug-31-22 08:30AM	Blue Water Vaccines to Present at H.C. Wainwrights 24th Annual Global Investment Conference in New York, NY (GlobeNewswire) -5.69%
Aug-24-22 02:00PM	Blue Water Vaccines to Present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HRT FINANCIAL LP	10% Owner	Apr 21 '26	Sale	0.69	49,710	34,300	33,649	Apr 22 02:59 PM
HRT FINANCIAL LP	10% Owner	Apr 17 '26	Buy	0.73	34,636	25,284	177,821	Apr 21 03:41 PM
HRT FINANCIAL LP	10% Owner	Apr 20 '26	Sale	0.75	94,462	70,846	83,359	Apr 21 03:41 PM
HRT FINANCIAL LP	10% Owner	Apr 16 '26	Sale	0.73	53,867	39,323	143,185	Apr 21 03:41 PM
HRT FINANCIAL LP	10% Owner	Apr 15 '26	Buy	0.76	92,554	70,341	197,052	Apr 16 02:30 PM
HRT FINANCIAL LP	10% Owner	Apr 14 '26	Buy	0.77	74,350	57,250	104,498	Apr 16 02:30 PM

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

Interim Chief Financial OfficerMs. Karina M. Fedasz

C.P.A.Mr. David Allan White C.A.

Global Head of Biologics OperationsMr. Andrew D. Skibo Ph.D.

Head of Business DevelopmentMr. Theodore Scott Yoho

Head of Science & DiscoveryDr. Ali I. Fattom Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ONCO

Onconetix Inc

Upgrade your Finviz experience